Lonza's new medium boosts and optimizes AAV production in insect cells
The TheraPEAK SfAAV Medium is specifically designed to support the development of safe, scalable, gene therapies.
In an effort to help biotechnology companies to fast track the development of safe gene therapies to treat a range of life-threatening conditions, Lonza has launched the first chemically defined, non-animal origin medium designed to increase Adeno Associated Virus (AAV) production in Spodoptera Fuigiperda Sf9 insect cells.
The new high-performance medium accelerates cell growth, increases productivity, and reduces process variability and costs, expediting time-to-market for safe, scalable, life-saving gene therapies.
Gene therapy holds great promise for the treatment of rare disorders and diseases, and viral vectors are commonly used to facilitate the delivery of the gene of interest into patient cells.
AAV has been established as a viral vector of choice, due to not replicating in patients, thus posing a lower health risk. Owing to their ability to be grown at high densities, the Sf9 insect cells are ideal for use as hosts for the production of large AAV quantities. To date, however, translational scientists and researchers have been challenged with the lack of a medium dedicated to AAV production in Sf9 insect cells.
The company reports that its TheraPEAK SfAAV Medium provides a cost and time-efficient solution for the production of AAV in Sf9 insect cells. Allowing for rapid cell growth, the TheraPEAK SfAAV Medium reduces processing time significantly, enabling cell infection one day earlier than similar media available on the market, and boosting laboratory performance.
Due to its chemically defined nature, the new hydrolysate free medium produces AAV that requires less purification, further decreasing the overall processing time and minimizing labour requirements. Furthermore, the TheraPEAK SfAAV Medium supports consistent cell growth throughout all phases of the culturing process, considerably reducing process variability.
As a chemically defined, non-animal origin product, the TheraPEAK SfAAV Medium is safer to use than media containing animal or human components, thereby facilitating regulatory compliance. Additionally, the medium is supplied with a US Food and Drug Administration drug master file, alleviating the relevant preparation and submission burden.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance